Introduction
============

Cisplatin (*cis*-diamminedichloroplatinum II or CDDP) is a platinum compound which has a broad role in the management of various solid malignancies such as head and neck, bladder, lung, ovaries, testicles, and uterus ([@B38]). However, during the course of chemotherapy, cisplatin may cause ototoxicity, nephrotoxicity, myelosuppression, and peripheral neuropathy ([@B37]). Among these undesirable effects, nephrotoxicity is the most important dose limiting adverse effect of cisplatin therapy, which primarily affects the S3 segment of the proximal tubules ([@B6]). It accounts for up to 60% of acute kidney injury cases acquired from the hospital and is associated with remarkably high morbidity and mortality and approximately one fourth of patients initiated on high-dose cisplatin have severe renal dysfunction while one third experience kidney injury within few days of receiving cisplatin ([@B38]). Clinically, cisplatin induced renal dysfunction manifests as decline in renal plasma flow and glomerular filtration rate with an increase in serum creatinine and blood urea nitrogen ([@B32]). The proposed molecular mechanisms underlying cisplatin nephrotoxicity involve oxidative stress, DNA damage, apoptosis and exaggerated inflammatory response ([@B40]).

The oxidative stress has emerged as the main mechanism in cisplatin-induced nephrotoxicity ([@B11]; [@B38]). It has been reported that excess reactive oxygen species (ROS) production as well as antioxidant system depletions are consequent to cisplatin administration ([@B10]). The likely sources of ROS during cisplatin administration include the mitochondrial electron transport chain system ([@B42]), xanthine oxidase ([@B59]), cytochrome P450 enzymes ([@B40]), and NADPH oxidase ([@B56]). Since, ROS are highly reactive and unstable; they may attack and modify cellular components such as lipids, proteins, and DNA, resulting in cellular stress ([@B21]). ROS accumulation also activates important signaling pathways, including apoptotic pathway, which leads to cell death in the event of cisplatin-induced nephrotoxicity ([@B51]). Cisplatin mediated oxidative stress provokes the stimulation of a cascade of signaling proteins, including MAPKs and NF-κB ([@B30]). This abnormal activation of MAPK and NF-κB leads to release of inflammatory cytokines subsequently aggravating the renal damage ([@B47]). The renal damage induced by cisplatin is managed using hydration/diuretics, renal function monitoring and adjustment of the cisplatin dose. However, renal toxicity still occurs despite the use of these measures. Therefore, taking the molecular pathways of cisplatin nephrotoxicity in consideration, exploration of more effective nephroprotective therapeutic options which would not affect the tumoricidal activity of cisplatin is essential.

Several strategies have been evaluated to minimize the nephrotoxicity caused by cisplatin. Recently, plant derived natural compounds and their active constituents are being evaluated for their beneficial effects in various pathophysiological conditions ([@B3]). *Emblica officinalis* (*E. Officinalis*) also known as Amla or Indian Gooseberry is a natural fruit that serves as a rich source of vitamin C ([@B26]). It also contains flavonoids, tannins, terpenoids and alkaloids which possess various biological activities ([@B24]). The active extracts of *E. Officinalis* have been demonstrated to exert a wide range of activities such as antioxidant in alcohol-induced oxidative damage in rat liver microsomes ([@B46]), anti-apoptotic in arsenic-induced apoptosis in thymocytes of mice ([@B49]), anti-inflammatory in rodent models of acute and chronic inflammation ([@B18]), anti-diabetic in type 2 diabetes in rats ([@B35]), anti-hypertensive in DOCA salt induced hypertension in rats ([@B5]) and anticancer in cervical cancer cells ([@B29]). Several studies have also been conducted to investigate its beneficial effect in kidney injury including cyclophosphamide induced renal injury ([@B20]) and mycotoxin induced renal toxicity ([@B55]). Thus, the present study was designed to investigate the beneficial effect of the dried fruit extract of *E. officinalis* (EO) on cisplatin mediated kidney injury by assessing its antioxidant, anti-apoptotic, and anti-inflammatory properties on the kidney and further to evaluate whether MAPK pathway is involved in mediating this renoprotection.

Materials and Methods {#s1}
=====================

Plant Extract
-------------

The dried fruit extract of *E. officinalis* (EO) was obtained from Sanat Products Limited, India (a WHO-GMP and ISO 9001 Accredited Herbal Extract Manufacturer Company). The batch number of EO was 048001. The extract contained 31.58% w/w of hydrolysable tannins emblicanin A and emblicanin B on dried weight basis.

Chemicals
---------

Cisplatin was obtained from Pfizer Products Pvt. Ltd., India. Blood urea nitrogen (BUN) and serum creatinine kits were procured from Transasia Bio-Medicals Ltd., India. Kits for Terminal deoxynucleotide transferase dUTP nick end labeling (TUNEL) assay (ApoBrduDNA fragmentation assay kit) (Biovision Inc. California), tumor necrosis factor-α (TNF-α) (Diaclone Tepnel Company, UK) and IL-6 (Ray Biotech, Inc. Norcross, GA, USA) were used. Primary antibodies against extracellular signal-regulated kinase 1/2 (ERK1/2), phospho-ERK1/2 (p-ERK1/2), c-Jun N-terminal kinase (JNK), phospho-JNK (p-JNK), Caspase-3, NF-κBp65, and β-actin were procured from cell signaling technology, USA. Antibodies for Bcl-2, Bax and p-38 were purchased from Abcam, UK. Phospho-p38 (p-p38) antibody was obtained from Santa Cruz biotechnology, USA. Secondary antibodies were from Merck Genei Pvt. Ltd., India. All other chemicals used were of analytical grade.

Experimental Animals
--------------------

Adult male albino Wistar rats aged 10--12 weeks old (weighing 150--200 g) were used for the study. All experimental procedures were conducted after approval by Institutional Animal Ethics Committee of All India Institute of Medical Sciences, New Delhi (IAEC no. 604/IAEC/2011) and conformed to the Indian National Science Academy Guidelines for care and use of animals in research. During the study period, animals were kept in polypropylene cages under conditions of ambient temperature (25 ± 2°C), relative humidity (60 ± 5%) and 12 h light/dark cycle and provided food pellets (Ashirwad Industries Ltd, Chandigarh, India) and tap water *ad libitum*.

A total of 36 male albino Wistar rats were randomly divided into six groups containing six rats per group. The test drug, EO, was dissolved in distilled water for administration to rats.

### Group 1 (Control)

Rats received distilled water (2 ml/kg; p.o.) for the period of 10 days.

### Group 2 (Cisplatin-Control)

Rats received distilled water (2 ml/kg; p.o.) for the period of 10 days and on the 7th day, a single injection of cisplatin (8 mg/kg; i.p.) was administered to induce nephrotoxicity ([@B30]).

### Groups 3--5 (Treatment Groups)

Rats received EO (150--600 mg/kg; p.o.) daily for the period of 10 days and on the 7th day, a single injection of cisplatin (8 mg/kg; i.p.) was administered to induce nephrotoxicity.

### Group 6 (EO Only)

Rats received EO (600 mg/kg; p.o.) for the period of 10 days.

On the 10th day, rats were anaesthetized with pentobarbitone sodium (60 mg/kg; i.p.) and chest cavity was opened. Blood was drawn *via* cardiac puncture, and centrifuged at 4000 rpm to separate serum which was stored at -20°C for measurement of BUN, serum creatinine, TNF-α and IL-6 levels. After sacrificing, one kidney from 6 rats per group was snap frozen in liquid nitrogen and preserved in -80°C and used for biochemical estimation. The second kidney from 3 rats per group was removed and preserved in 10% neutral buffered formalin for histopatholgical and TUNEL assay and kidney from the other 3 rats per group were snap frozen in liquid nitrogen and stored in -80°C for western blot analysis.

Assessment of Kidney Function Parameters
----------------------------------------

Serum creatinine and BUN levels were measured using respective commercially available kits.

Measurement of Renal Oxidant--Antioxidant Parameters
----------------------------------------------------

Kidney sample was removed from -80°C, thawed, weighed and 10% homogenate was prepared in ice-chilled phosphate buffer (0.1 M, pH 7.4). The tissue homogenate was divided into two parts. One part of this homogenate was used for the estimation of malondialdehyde (MDA) level and reduced glutathione (GSH) content. The other part of this tissue homogenate was centrifuged at 5000 rpm and supernatant thus obtained was used for the estimation of superoxide dismutase (SOD), catalase (CAT) enzyme activities and protein content.

### Estimation of MDA Level

MDA level was estimated by the method described by [@B39]. To the 0.1 ml tissue homogenate, 0.5 ml of 8.1% sodium dodecyl sulfate, 1.5 ml of 20% acetic acid and 1.5 ml of 0.8% thiobarbituric acid was added, vortexed and heated at 95°C for 60 min. After cooling, 5 ml of butanol:pyridine (15:1) mixture was added to extract pink color complex. The pink organic layer was separated and absorbance read at 532 nm. The amount of MDA was calculated by extrapolation from the MDA standard curve and expressed as nmole/g tissue.

### Estimation of GSH Content

GSH was measured by the method described by [@B33]. Firstly, homogenate was centrifuged with an equal volume of 10% trichloroacetic acid. To the 0.1 ml of supernatant, 3 ml Na~2~HPO~4~ (0.3 M; pH 8.0) and 0.5 ml of 5,5′-dithiobis (2-nitrobenzoic acid) prepared in 1% trisodium citrate were added and mixed thoroughly. The absorbance of yellow color formed was read at 412 nm. The amount of GSH was determined by extrapolation from standard curve and expressed as μmole/g tissue.

### Estimation of SOD

Superoxide dismutase enzyme activity was determined by the method described by [@B31]. To the 0.1 ml supernatant, 2.95 ml of phosphate buffer (0.1 M; pH 8.4) and 0.05 ml of pyrogallol (7.5 mM) was added and the change in absorbance was recorded at an interval of 60 s for 2 min at 420 nm. One unit of enzyme activity was defined as the amount of enzyme required to produce 50% inhibition of pyrogallol autoxidation under assay conditions and expressed as U/mg protein.

### Estimation of CAT

CAT enzyme activity was estimated by the method described by [@B1]. To the 0.05 ml of supernatant, 1 ml of phosphate buffer (50 mM; pH 7.0) and 1.0 ml of hydrogen peroxide (H~2~O~2~) was added. Immediately, thereafter, change in the absorbance was recorded for 30 s at an interval of 5 s at 240 nm. One unit of CAT enzyme activity is equal to 1 μmol of H~2~O~2~ decomposed per min and expressed as U/mg protein.

### Estimation of Protein Content

Protein was measured by a method described by [@B7]. To the supernatant, Bradford reagent was added and vortexed. Blue color formed was measured at 595 nm. The amount of protein was determined by standard curve and expressed as mg/ml.

Measurement of Serum Pro-inflammatory Cytokines Level
-----------------------------------------------------

TNF-α and IL-6 levels were assessed in serum using commercially available ELISA kits as per manufacturer instructions.

Histopathological Examination
-----------------------------

For histopathological evaluation, paraffin blocks were made from kidney tissue preserved in formalin. The tissue sections of 5-μm thickness were cut using microtome (Leica RM 2125, Germany). These sections were stained with hematoxylin and eosin (H&E) and studied under light microscope (Dewinter Technologies, Italy).

TUNEL Assay
-----------

TUNEL assay was performed for detection of apoptosis in the renal tissue. TUNEL assay was performed according to the method described by [@B30]. Briefly, sections were incubated with Proteinase K for 30 min to enhance tissue permeability and then treated with 30% H~2~O~2~ in methanol for 15 min to diminish any endogenous peroxidase activity. Later, sections were incubated with complete labeling reaction buffer and antibody solution, each for 1 h and 30 min. Following this, 3,3′-diaminobenzidine (DAB) solution was added and at least five fields in each slide were checked for any TUNEL positive cells in each group.

The pathologist evaluating histopathological and TUNEL slides was blinded to the treatment groups.

Western Blot Analysis
---------------------

For western blot analysis, kidneys were removed from -80°C, thawed and weighed. Then tissues were homogenized in Radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 10% Triton X-100, 0.5% Sodium deoxycholate, 0.1% Sodium dodecyl sulfate, 50 mM Tris base), along with protease inhibitor (Sigma Aldrich, USA). The homogenate was centrifuged at 12000 rpm for 20 min at 4°C and supernatant was used for measurement of protein concentration by using the method described by [@B7]. Protein equivalent to 40 μg was separated by the sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were then transferred to a nitrocellulose membrane and then blocked with 3% bovine serum albumin (BSA) for 1 h. After that, membrane was blocked with primary antibodies for ERK1/2, p-ERK1/2, JNK, p-JNK, p38, p-p38, Bcl-2, Bax, Caspase-3, NF-κBp65 and β-actin (1:3000) overnight at 4°C. The primary antibodies were detected with HRP-conjugated secondary antibodies (1:5000) for 2 h at room temperature. The antigen-antibody reaction was then visualized with enhanced chemiluminscence (ECL) kit according to manufacturer's instructions. The band intensity was measured using image-j software.

Statistical Analysis
--------------------

Data of all experimental groups were analyzed by one way analysis of variance (ANOVA) followed by *post hoc* Tukey-Kramer multiple comparison test using the Graph Pad InStat software. Data are expressed as mean ± SEM and values for *P* \< 0.05 were considered as statistically significant.

Results
=======

Effect of EO on Kidney Function Parameters
------------------------------------------

The kidney function parameters such as serum creatinine and BUN levels were measured in all treatment groups to assess renal function. Cisplatin injection resulted in significant increase in serum creatinine (*P* \< 0.001) and BUN levels (*P* \< 0.001) in comparison to control group. This elevation in serum creatinine and BUN levels suggests significant kidney damage and confirmed the induction of nephrotoxicity in cisplatin control group. EO (600 mg/kg) pretreatment significantly (*P* \< 0.01) normalized serum creatinine and BUN levels as compared to cisplatin-control group. However, no significant effect was observed at two lower doses (150 and 300 mg/kg) (**Table [1](#T1){ref-type="table"}**).

###### 

Effect of EO on renal function tests (serum creatinine and BUN) and biochemical parameters.

  Groups        Sr. Creatinine (mg/dl)   BUN (mg/dl)             MDA (nmol/g tissue)   GSH (μmol/g tissue)   SOD (U/mg protein)   CAT (U/mg protein)
  ------------- ------------------------ ----------------------- --------------------- --------------------- -------------------- --------------------
  Control       0.57 ± 0.028             28.59 ± 1.62            60.50 ± 3.44          0.29 ± 0.012          3.98 ± 0.41          4.73 ± 0.42
  Cis-C         1.45 ± 0.052^∗∗∗^        53.95 ± 2.67^∗∗∗^       109.81 ± 3.75^∗∗∗^    0.16 ± 0.014^∗∗∗^     2.42 ± 0.33^∗∗^      2.36 ± 0.65^∗∗^
  EO 150+Cis    1.37 ± 0.075^†††^        50.35 ± 1.72^†††^       102.94 ± 4.54^†††^    0.18 ± 0.015^†††^     2.91 ± 0.18          3.61 ± 0.53
  EO 300+Cis    1.29 ± 0.048^†††^        46.01 ± 2.05^†††^       96.63 ± 4.63^†††^     0.21 ± 0.012^††^      3.02 ± 0.19          4.13 ± 0.30
  EO 600+Cis    1.18 ± 0.057^†††\#\#^    42.46 ± 1.66^†††\#\#^   91.66 ± 3.38^†\#^     0.24 ± 0.014^\#\#^    3.57 ± 0.15^\#^      4.42 ± 0.26^\#^
  EO 600 only   0.62 ± 0.031             31.65 ± 1.35            71.01 ± 3.71          0.32 ± 0.012          3.96 ± 0.18          4.92 ± 0.33

BUN, blood urea nitrogen; MDA, malondialdehyde; GSH, reduced glutathione; SOD, superoxide dismutase; CAT, catalase. Data are expressed as mean ± SEM of 6 rats per group.
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Effect of EO on Renal Oxidant--Antioxidant Parameters
-----------------------------------------------------

In cisplatin-control rats, there was a significant (*P* \< 0.001) increase in the level of MDA, a marker of lipid peroxidation, along with reduction in the level of antioxidants GSH (*P* \< 0.001), SOD (*P* \< 0.01), and CAT (*P* \< 0.01) in comparison to control group. Interestingly, EO (600 mg/kg) pretreatment significantly restored the kidney antioxidant status. This is depicted by increase in the activities of GSH (*P* \< 0.01), SOD (*P* \< 0.05) and CAT (*P* \< 0.05) and decrease in the level of MDA (*P* \< 0.05) as compared to the cisplatin-control rats. Moreover, the two lower doses (150 and 300 mg/kg) of EO failed to exert any beneficial effect on the kidney antioxidant status (**Table [1](#T1){ref-type="table"}**).

Effect of EO on Serum Inflammatory Cytokines Level
--------------------------------------------------

Cisplatin administration is known to release pro-inflammatory cytokines in serum. Thus, there was a significant (*P* \< 0.001) increase in serum pro-inflammatory cytokines level (TNF-α and IL-6) in the cisplatin-control group as compared to the rats in the control group. EO (600 mg/kg) pretreatment significantly (*P* \< 0.01) prevented the increase in the serum cytokines level as compared to the cisplatin-control group. However, no significant difference in the levels of these cytokines was observed with the lower doses of EO (150 and 300 mg/kg) (**Table [2](#T2){ref-type="table"}**).

###### 

Effect of EO on serum pro-inflammatory cytokines level.

  Groups        TNF-α (pg/ml)         IL-6 (pg/ml)
  ------------- --------------------- ---------------------
  Control       37.35 ± 1.49          9.5 ± 0.46
  Cis-C         58.17 ± 2.38^∗∗∗^     17.92 ± 0.91^∗∗∗^
  EO 150+Cis    54.95 ± 2.92^†††^     16 ± 0.90^†††^
  EO 300+Cis    50.07 ± 1.87^††^      14.21 ± 0.94^††^
  EO 600+Cis    46.46 ± 1.84^†\#\#^   12.62 ± 0.65^†\#\#^
  EO 600 only   38.51 ± 1.64          10.29 ± 0.65

TNF-α, tumor necrosis factor-α; IL-6, interleukin-6. Data are expressed as mean ± SEM of 6 rats per group.
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Effect of EO on Renal Histopathology
------------------------------------

The histopathological evaluation of control and EO only groups demonstrated normal architecture of tubules with no evidence of inflammation (**Figures [1A,F](#F1){ref-type="fig"}**). The kidney sections from the cisplatin-control rats showed tubular atrophy, denudation of epithelium and infiltration of inflammatory cells (**Figure [1B](#F1){ref-type="fig"}**). In the groups, pretreated with 150 and 300 mg/kg dose of EO, there was marked and moderate tubular damage and inflammation respectively (**Figures [1C,D](#F1){ref-type="fig"}**). However, the highest dose of EO i.e., 600 mg/kg exerted significant nephroprotection and a marked absence of tubular necrosis and inflammation in the kidneys was observed (**Figure [1E](#F1){ref-type="fig"}**).

![**Light microscopic study (H&E) of renal tissue in various experimental groups. (A)** Control; **(B)** Cis-C; **(C--E)** EO 150, 300, 600 mg/kg+Cis respectively; **(F)** EO 600 mg/kg only. (→): acute tubular necrosis; (*n* = 3; 20X; scale bar 100 μm).](fphar-07-00350-g001){#F1}

Thus, on the basis of results of the above mentioned parameters, EO at the dose of 600 mg/kg was found to exert maximum nephroprotection. Hence, this dose was used for further TUNEL and western blot analysis.

Effect of EO on Apoptosis and Inflammation
------------------------------------------

The apoptosis in the renal tissue was assessed by detecting the expression of apoptotic proteins in all groups. In cisplatin-control group, there was significantly increased expression of pro-apoptotic proteins \[Bax (*P* \< 0.001) and Caspase-3 (*P* \< 0.001)\] and decreased expression of Bcl-2 (*P* \< 0.001), an anti-apoptotic protein. Furthermore, there was increased DNA fragmentation and increased number of TUNEL positive cells in the cisplatin-control group as compared to the control group. However, EO (600 mg/kg) treatment group reduced the apoptosis as there was significantly (*P* \< 0.05) increased expression of Bcl-2 and decreased expression of Bax, Caspase-3 along with decreased DNA fragmentation as compared to cisplatin-control group. This confirms the anti-apoptotic effect of EO in renal tissue (**Figures [2](#F2){ref-type="fig"}** and **[3](#F3){ref-type="fig"}**).

![**Effect of EO on TUNEL positivity (**A--C**; 20X; scale bar 100 μm) in various experimental groups. (A)** Control; **(B)** Cis-C; **(C)** EO 600 mg/kg+Cis. (→): tubular cell apoptosis.](fphar-07-00350-g002){#F2}

![**Effect of EO on **(A)**: NF-κBp65; **(B)** Bcl-2; **(C)** Bax; **(D)** Caspase-3 levels in various experimental groups.** Data are expressed as mean ± SEM of 3 rats per group. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 versus control group; ^†^*P* \< 0.05, ^††^*P* \< 0.01, ^†††^*P* \< 0.001 versus control group; ^\#^*P* \< 0.05 versus Cis-C group.](fphar-07-00350-g003){#F3}

Further, western blot analysis was performed to determine the expression of NF-κBp65 in the renal tissue. Cisplatin-control rats demonstrated significantly (*P* \< 0.01) increased level of NF-κBp65 whereas treatment with EO (600 mg/kg) attenuated this effect (*P* \< 0.05) (**Figure [3](#F3){ref-type="fig"}**).

Effect of EO on MAPK Signaling Pathway
--------------------------------------

In cisplatin-control group, there was increased phosphorylation of ERK1/2, JNK and p38 proteins as compared to control rats. The increased phosphorylation of these proteins mediated apoptosis and inflammation in the cisplatin-control group. Contrary to this, EO (600 mg/kg) treatment halted the activation of this pathway and prevented apoptosis and inflammation in the renal tissue (**Figure [4](#F4){ref-type="fig"}**).

![**Effect of EO on **(A)** ERK1/2 and p-ERK1/2; **(B)** JNK and p-JNK; **(C)** p38 and p-p38 in various experimental groups.** Data are expressed as mean ± SEM of 3 rats per group. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 versus control group; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 versus Cis-C group.](fphar-07-00350-g004){#F4}

Discussion
==========

The current study has demonstrated the renoprotective effect of EO in cisplatin-induced acute renal toxicity in rats. The administration of EO virtually ameliorated most of the deleterious effects of cisplatin. This renoprotection was evident from improved functional as well as structural renal profiles, blunting of oxidative stress, inflammation, and apoptosis. Our results further provided evidence that this improvement was mediated by suppression of the MAPK signaling cascade.

Cisplatin's chemotherapeutic applicability is limited by renal toxicity and the latter occurs due to accumulation of cisplatin into the renal tubular cells which subsequently leads to renal tubular cell injury and renal cell death which appears histologically as tubular atrophy ([@B41]). Many studies have proposed that cisplatin is also injurious to renal vasculature which results in decreased blood flow leading to ischemic injury of the kidneys, appearing as a decline in the glomerular filtration rate which is reflected as increased serum creatinine and BUN levels ([@B58]). In our study, we observed increased levels of serum creatinine and BUN suggesting renal damage due to cisplatin. Serum creatinine is the waste metabolic product and is formed due to breakdown of creatine phosphate in muscle. Normally, it is excreted by the kidneys, primarily by glomerular filtration but also by proximal tubular secretion with little or no reabsorption. If there is deterioration in kidney function, serum level of creatinine rises ([@B13]; [@B8]; [@B14]). Also, concomitant decline in urinary creatinine clearance is observed vis a vis raised serum creatinine levels. Infact, decrease in urinary creatinine clearance due to cisplatin-induced kidney injury has been reported by other researchers ([@B43]; [@B36]). Although, we have not measured the urinary creatinine clearance in this particular study, the changes in serum creatinine and BUN levels observed here were clearly accompanied by changes in renal histology, further suggesting renal function deterioration in cisplatin-treated animals. There was marked renal tubular atrophy and denudation of epithelium following intraperitoneal administration of 8 mg/kg cisplatin. Administration of EO 600 mg/kg, significantly normalized serum creatinine and BUN levels and also preserved the histology of renal tubular cells.

Numerous studies have depicted the key role of oxidative stress in the pathophysiology of cisplatin-induced renal cell death ([@B51]). Once cisplatin reaches the tubular cells, it rapidly reacts with thiol-containing molecules including glutathione by being converted to a highly reactive electrophile. This positively charged electrophile is generated by replacement of the chloride ligands of cisplatin with water molecules. Cisplatin also increases ROS synthesis by inducing mitochondrial dysfunction and disrupting the electron transport chain. Due to their unstable configuration, ROS reacts with membrane lipids, cellular proteins and DNA resulting in their modification leading to cellular stress ([@B40]). Lipid peroxidation is a consequence of excessive ROS production. It leads to increased level of MDA (a lipid peroxidation marker). The rise in MDA levels following cisplatin administration *in vivo* has been observed in our study and has also been reported by other workers ([@B60]). Excessive ROS is tackled by endogenous antioxidants. However, when the synthesis of ROS overrides its destruction, there is overconsumption of these antioxidants. This consumption has also been demonstrated previously in cisplatin nephrotoxicity models ([@B2]). Similarly, there was consumption of glutathione and other endogenous antioxidants such as SOD and CAT in the cisplatin-control group of our study. However, pretreatment with EO maintained glutathione and other antioxidants at near normal levels in the renal tissue. This supports the antioxidant activity of EO which has been documented in the past ([@B17]; [@B12]; [@B50]). Previous studies have shown that active constituents such as emblicanins A and B, gallic acid, and ellagic acids present in *E. officinalis* are responsible for its antioxidant activity ([@B15]). Furthermore, free radical scavenging property of *E. officinalis* has been reported to be near to that of [L]{.smallcaps}-ascorbic acid, a well known antioxidant ([@B34]).

Though oxidative stress is a known promoter of apoptosis, cisplatin itself directly induces apoptotic cell death which has been shown by *in vitro* and *in vivo* studies ([@B54]; [@B48]; [@B62]). According to past reports, renal tubular epithelial cell apoptosis induced by cisplatin is primarily *via* the mitochondrial pathway ([@B27]). Cisplatin induced apoptosis has been shown to be regulated by the pro-apoptotic protein Bax and the anti-apoptotic protein Bcl-2 ([@B22]). It has been shown that cisplatin induces activation of Bax genes ([@B57]). Bax protein eventually undergoes a conformational change and binds to mitochondrial membrane and subsequently causes the release of cytochrome c from mitochondria leading to apoptosis ([@B53]). In contrast, the anti-apoptotic protein Bcl-2 stabilizes the mitochondrial membrane potential thereby inhibiting cytochrome c release and inhibiting apoptosis ([@B9]). Therefore, Bax and Bcl-2 are crucial in regulating apoptosis. In our experiment, significantly higher Bax and Caspase-3 and lower Bcl-2 levels were observed in cisplatin-control group. This shows that cisplatin increases Bax and Caspase-3 while lowering Bcl-2 expression of renal tissues whereas pretreatment with EO (600 mg/kg) decreased the Bax and Caspase-3 and increased Bcl-2 levels. TUNEL assay was performed to assess the DNA fragmentation. The TUNEL positivity was observed to be high in cisplatin treated rats and significantly reduced in EO pretreated group. These findings support the previously documented anti-apoptotic activity of *E. Officinalis* ([@B49], [@B50]). Thus, it can be proposed that the renoprotection of EO is mediated by its antioxidant and anti-apoptotic properties.

Strong evidence suggests that the pathogenesis of cisplatin induced renal cell apoptosis is associated with the release of inflammatory cytokines and mediators, including IL-1, IL-6, and TNF-α ([@B61]; [@B19]; [@B63]). Additionally, NF-κB which is a transcription factor regulating the modulation of inflammatory and immunomodulatory genes, is associated with the process of cisplatin induced renal inflammation ([@B4]). NF-κB activity is inhibited by the specific IκB in the cytoplasm, the latter being rapidly cleared by IKKβ upon activation of NF-κB. NF-κB is released and then translocates to the nucleus, where it activates the transcription of target genes ([@B28]). Our study has shown that cisplatin-control group has a higher expression of activated NF-κB, IL-6 and TNF-α in comparison to the control rats. Interestingly, EO significantly attenuated the levels of inflammatory cytokines and also blunted the expression of NF-κB. The polyphenol rich components of ethanolic extract of *E. officinalis* have previously been demonstrated to reduce expression of NF-κB in a similar fashion ([@B25]). Therefore, the attenuation of cisplatin induced nephrotoxicity with EO in our study may also be mediated by the anti-inflammatory property of EO.

Based on the ability of EO to suppress the phosphorylation of members of the NF-κB cascade pathway and inflammation, we further investigated the effect of EO on the upstream signaling components of NF-κB, the MAPK family. MAPK family comprises of three major serine/threonine kinase proteins such as ERK 1/2, JNK and p38 which are associated with cell growth and differentiation, and are extensively linked to inflammation, apoptosis and cell death. Several *in vitro* and *in vivo* studies have demonstrated the role of p38 and JNK in cisplatin-induced nephrotoxicity ([@B44], [@B45]; [@B16]). ERK1/2 promotes apoptosis by decreasing the production of cytochrome c, phosphorylation of caspase-3, and accelerating the translocation of Bax from cytosol to mitochondria during cisplatin-induced renal cell death ([@B23]). Cisplatin-induced phosphorylation of JNK induces inflammation of the kidney tubules, apoptosis, and kidney dysfunction ([@B28]). As anticipated, in our study, cisplatin injection increased the phosphorylation of p38, ERK1/2 and JNK. Pre-treatment with EO, however, ameliorated this increase. Our results are also in line with our study which has demonstrated ERK1/2 modulated effect of *E. officinalis* ([@B52]). Hence, we can convincingly propose that EO mediates its nephroprotective action by regulating MAPK signaling pathway.

In summary, our findings demonstrate that EO treatment alleviates the cisplatin-induced cytotoxicity in kidney through suppressing the ROS mediated activation of MAPKs and NF-κB signaling cascades. Furthermore, EO treatment inhibits the synthesis of intracellular inflammatory cytokines and mediators. Our study suggests that EO has good potential and may be further evaluated clinically for treating cisplatin-induced nephrotoxicity.
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